INVECTYS THERAPEUTICS

Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. It was founded in 2010 by Pierre Langlade Demoyen and Simon Wayne-Hobson and is based in Paris. Invectys develops a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients. This allows virtually all cancers to be targeted. Invectys focuses its efforts on two highly prevalent tumor antigens: the nearly-universal tumor antigen telomerase that is critical to uncontrolled cell growth, and the HLA-G immune checkpoint expressed in over 50% of cancers.